Jan van de Winkel, Genmab CEO
Fresh off approval, AbbVie and Genmab's CD3xCD20 bispecific Epkinly scores in another type of blood cancer
Just over a month after landing their first approval for epcoritamab, now branded as Epkinly, Genmab and AbbVie have a fresh slate of data …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.